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Cellular stress by DNA damage induces checkpoint kinase-2 (CHK2)-mediated phosphorylation and stabilization of the
E2F1 transcription factor, leading to induction of apoptosis by activation of a subset of proapoptotic E2F1 target genes,
including Apaf1 and p73. This report characterizes an interaction between the aryl hydrocarbon (Ah) receptor (AHR), a
ligand-activated transcription factor, and E2F1 that results in the attenuation of E2F1-mediated apoptosis. In Ahrⴚ/ⴚ
fibroblasts stably transfected with a doxycycline-regulated AHR expression vector, inhibition of AHR expression causes
a significant elevation of oxidative stress, ␥H2A.X histone phosphorylation, and E2F1-dependent apoptosis, which can be
blocked by small interfering RNA-mediated knockdown of E2F1 expression. In contrast, ligand-dependent AHR activation protects these cells from etoposide-induced cell death. In cells expressing both proteins, AHR and E2F1 interact
independently of the retinoblastoma protein (RB), because AHR and E2F1 coimmunoprecipitate from extracts of RBnegative cells. Additionally, chromatin immunoprecipitation assays indicate that AHR and E2F1 bind to the Apaf1
promoter at a region containing a consensus E2F1 binding site but no AHR binding sites. AHR activation represses Apaf1
and TAp73 mRNA induction by a constitutively active CHK2 expression vector. Furthermore, AHR overexpression blocks
the transcriptional induction of Apaf1 and p73 and the accumulation of sub-G0/G1 cells resulting from ectopic overexpression of E2F1. These results point to a proproliferative, antiapoptotic function of the Ah receptor that likely plays a role
in tumor progression.

INTRODUCTION
Members of the E2F family of transcription factors are critical regulators of the G1/S phase transition of the cell cycle,
during which their transcriptional activity is generally controlled through interaction with retinoblastoma (RB) family
proteins. In addition, E2F proteins have functions beyond
the G1/S phase transition that impact cell proliferation in a
variety of ways (Dimova and Dyson, 2005). The E2F family
consists of six extensively characterized and three less wellstudied members. E2F1, -2, and -3a are potent activators of
transcription, bind exclusively to RB-p105, and are cyclically
expressed during the cell cycle. E2F3b and -4, which can
interact with RB-p107 and -p130, and E2F5, which binds
only to p130, are poor transcriptional activators, and they
function mainly as repressors through their recruitment of
RB proteins to E2F-regulated promoters (Dyson, 1998; Nevins, 1998; DeGregori and Johnson, 2006). In general, the E2Fs
with transactivator activity promote cell cycle progression,
whereas the E2Fs with transrepressor activity function in
This article was published online ahead of print in MBC in Press
(http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E08 – 04 – 0359)
on June 4, 2008.
Present addresses: * Novartis Pharma AG, CH-4132 Muttenz, Switzerland; † Laboratory of Molecular Toxicology, National Institute of
Environmental Health Sciences, Research Triangle Park, NC 27709;
‡
Kimmel Cancer Center, Thomas Jefferson University, Philadelphia,
PA 19107.
Address correspondence to: Alvaro Puga (alvaro.puga@uc.edu).
© 2008 by The American Society for Cell Biology

cell cycle exit and differentiation (Dimova and Dyson, 2005).
E2F6-8 are distinct from the other E2F members, lacking the
transactivation and RB-binding domains, and they repress
transcription in an RB-independent manner (Frolov and
Dyson, 2004; DeGregori and Johnson, 2006).
The best-characterized function of E2F is its ability to
regulate the G1/S phase transition of the cell cycle. E2F
proteins exert control over the cell cycle by modulating the
transcription of a variety of essential cell cycle control genes,
including cell cycle regulators, RB and related pocket proteins, enzymes for nucleotide biosynthesis, and proteins required for DNA replication (Trimarchi and Lees, 2002). RB
modulates E2F-dependent transcription in at least two ways.
First, the physical binding of RB to E2F directly inhibits the
transactivation activity of E2F. Second, the association of RB
with chromatin-modifying corepressor proteins mediates
active repression of E2F-responsive genes (Dyson, 1998;
Harbour and Dean, 2000; Ferreira et al., 2001). Repressor
E2F/RB complexes are prevalent in G0/early G1 phases, and
they are disrupted in late G1, resulting primarily from the
phosphorylation of RB proteins by cyclin D-CDK4/6 and
cyclin E-CDK2 complexes. Late in G1, activator E2Fs turn on
the transcription of genes required for entry into S phase and
DNA synthesis (Trimarchi and Lees, 2002; DeGregori, 2002;
Stevaux and Dyson, 2002). However, the ability of a particular E2F protein to either induce S phase, senescence, or
some other outcome is dependent on the cellular context and
on the particular groups of up- or down-regulated genes
(Dimova and Dyson, 2005).
In addition to its well-established proliferative function,
E2F1 has also been implicated in the induction of apoptosis
3263

J. L. Marlowe et al.

through p53-dependent and p53-independent mechanisms
(Phillips et al., 1997; Phillips and Vousden, 2001). Several
genes involved in the activation or execution of the apoptotic program are transcriptionally up-regulated by E2F1 overexpression or stabilization in response to DNA damage or to
loss of RB, including the genes encoding INK4a/ARF,
APAF-1, caspase-7, and TAp73, the proapoptotic p73 variant
(Muller et al., 2001; Lin et al., 2001; Nahle et al., 2002; Furukawa et al., 2002; Pediconi et al., 2003; DeYoung and Ellisen, 2007). In human cells, E2F1 stabilization in response to
DNA damage results from checkpoint kinase-2 (CHK2)–
dependent phosphorylation at Ser364 (Stevens and La
Thangue, 2004). Of all E2F family members, induction of
apoptosis is predominantly a function of E2F1, with other
E2Fs exhibiting a reduced propensity to mediate cell death,
but the mechanisms of gene-specific regulation and proproliferative versus proapoptotic target gene selection by E2F1
are not yet fully understood (DeGregori and Johnson, 2006).
The Ah receptor (AHR) is a ligand-activated transcription
factor that belongs to the basic-region helix-loop-helix
(bHLH)/Per-Arnt-Sim (PAS) family of proteins. Prototypical AHR ligands include many polycyclic and halogenated
aromatic compounds, such as benzo关a兴pyrene (B关a兴P) and
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). The unliganded AHR is a cytosolic protein that translocates to the nucleus upon ligand binding and dimerizes with a second
bHLH/PAS protein, the AHR nuclear translocator (ARNT),
to form a heterodimeric transcription factor. AHR/ARNT
complexes bind to canonical DNA consensus sequences and
initiate transcription of genes coding for many phase I and
phase II detoxification enzymes (Hankinson, 1995). In addition to its role in the regulation of drug metabolism, evidence dating back more than 20 years shows that the AHR
plays a central role in the regulation of cell proliferation.
AHR activation by ligand or by deletion of the ligandbinding domain alters several cell cycle and signaling pathways, including those required for normal cell cycle regulation (Puga et al., 2002; Chang et al., 2007). Most evidence
shows that AHR activation delays cell cycle progression and
G1 to S phase transition, although this effect seems to be
cellular context specific, because in rat oval progenitor cells
the AHR promotes rather than delays cell cycle progression
(Weiss et al., 2008). A canonical RB-binding cyclin D-like
motif in the AHR protein sequence mediates a direct interaction between AHR and RB, and experimental work focused on the characterization of this interaction as the mediator of AHR-dependent cell cycle delay (Ge and Elferink,
1998; Puga et al., 2000; Marlowe et al., 2004; Huang and
Elferink, 2005) has shown that the activated AHR cooperates
with RB in its ability to repress E2F-dependent transcription
and delay cell cycle progression (Puga et al., 2000; Strobeck
et al., 2000).
Paradoxically, embryo fibroblasts from Ahr gene-knockout mice also show a relative delay in cell cycle progression,
which has been primarily associated with posttranscriptional stabilization of Tgfb1 mRNA (Chang et al., 2007). In
these cells, several E2F transcriptional targets with AHR and
E2F binding motifs in their promoters, conserved in both the
human and mouse sequences (Supplemental Tables S1 and
S2), were also found to be AHR targets, being repressed by
both E2f1 and Ahr ablation (Supplemental Figure S1). These
observations led us to hypothesize that AHR could directly
interact with and modulate the transcriptional activity of
E2F. We report here that inhibiting the expression of AHR
triggers an increase in oxidative stress and DNA damage,
leading to induction of E2F1-dependent apoptosis. Conversely, AHR activation leads to formation of AHR-E2F1
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protein complexes, resulting in inhibition of E2F1-dependent gene expression and apoptosis.
MATERIALS AND METHODS
Cell Lines, Growth Conditions, and Chemical Treatments
Mouse Hepa-1c1c7 hepatoma cells and human osteosarcoma Saos-2 cells were
maintained in minimal essential medium-␣ (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Invitrogen), antibiotic/antimycotic
solution (Sigma-Aldrich, St. Louis, MO), and 26 mM NaHCO3 at 37°C in a
humidified 5% CO2 atmosphere. The stable transfectant TET-OFF cell line
Off*Ahrb (Chang et al., 2007) was derived from mouse embryo fibroblasts
(MEFs) of AHR knockout mice by sequential retroviral insertion of a vector
expressing the regulatory tetracycline receptor protein and a second TETOFF–regulated vector expressing the high-affinity AHR encoded by the Ahrb1
allele. The cells were grown in medium containing 600 g/ml G418 (Invitrogen), 3 g/ml puromycin (A.G. Scientific, San Diego, CA), and 400 g/ml
hygromycin (Calbiochem, San Diego, CA). To down-regulate AHR expression
in these cells, doxycycline (Dox; Sigma-Aldrich), a tetracycline analog, was
used at a final concentration of 5 g/ml. Wild-type MEFs from C57BL/6J
mice were prepared by standard techniques from 14.5-d-old fetuses and
grown in ␣-minimal essential medium as described above. MEFs from E2f⫺/⫺
mice were a gift of G. Leone (The Ohio State University). When indicated,
cultures were treated with TCDD at a final concentration of 5 nM in dimethyl
sulfoxide (DMSO) vehicle, never to exceed 0.1% of the final volume, and
control cultures were treated with an equivalent volume of DMSO. Cell
survival after etoposide treatment was determined as described previously
(Chang et al., 2007). Briefly, cells were seeded in 24-well plates at concentrations ranging from 12,500 to 50,000 cells/well and exposed to the etoposide
concentrations indicated in the relevant figures. After 48 h, cells were washed
with phosphate-buffered saline (PBS), fixed in 70% ethanol, and incubated
with 5 g/ml Hoechst 33258 (Aldrich Chemical, Milwaukee, WI) at room
temperature in the dark for 30 min. Fluorescence at 355/460 nm was measured in a Wallac Victor2 1420 plate reader (PerkinElmer Wallac, Gaithersburg, MD). Saos-2 cells do not express AHR, as determined from the lack of
expression of a transfected AHR/ARNT-responsive luciferase reporter plasmid and by immunoblot analysis. Hepa-1 cells do not express RB, as determined by both immunoblot and reverse transcription-polymerase chain reaction (RT-PCR) analysis.

Plasmid and Adenoviral Constructs
The plasmid pcDNAI/B6AHR, used to express the high-affinity murine AHR,
and its truncation mutant derivatives, have been described previously (Marlowe et al., 2004). Expression of the peptides encoded by each AHR truncation
mutant presented in Supplemental Figure S2 was confirmed by Western blot
(data not shown). The reporter plasmid p3XE2FLuc, containing three E2Fresponsive elements, has also been described previously (Whitaker et al.,
1998). The kinase-dead (KD) and constitutively active (CA) CHK2 expression
vectors were a gift of P. Stambrook (University of Cincinnati). The AdEasy XL
Adenoviral Vector System (Stratagene, La Jolla, CA) was used to generate
recombinant adenovirus for the expression of the high-affinity variant of the
murine AHR. A DNA fragment containing the AHR cDNA was removed
from the pcDNAI/B6AHR vector and cloned into the pShuttle-cytomegalovirus (CMV) vector to yield the pShuttle-CMV-B6AHR plasmid. This
plasmid was linearized and used to transform BJ5183-AD-1 cells, containing the adenovirus plasmid pAdEasy-1, to produce the recombinant adenoviral plasmid pAdB6AHR. For control experiments, pShuttle-CMVLacZ was similarly processed.

Adenovirus Production and Infection
AD293 cells (Stratagene) transfected with adenoviral plasmids were harvested when 80 –90% of the cells detached from the growth plates. Cell pellets
were resuspended in PBS and lysed by four rounds of freezing/thawing. An
aliquot of the primary virus stock was used for a first round of amplification
and purified virus from this first amplification was used for large-scale
production of the final virus stock, which was purified by cesium chloride
density gradient centrifugation. Saos-2 cells were infected with purified adenovirus containing genes for the expression of LacZ, AHR, RB, and E2F1.
Infections were carried out using 100 plaque-forming units (pfu) per cell for
3 h in complete growth medium. After infection, cells were washed twice with
PBS, fed fresh growth medium, and harvested after 24 h for coimmunoprecipitation assays.

Transfections and Reporter Assays
Transfection of small interfering RNAs (siRNAs) was done by procedures
described previously (Schnekenburger et al., 2007a) based on the recommended manufacturer’s neofection protocol (Ambion, Austin, TX). siRNA
duplexes were used at a final concentration of 50 nM for predesigned SilencerR E2F1 siRNAs (ID nos. 160617 and 160618) and scrambled negative
control (catalog no. 4611). At 48 h posttransfection, cells were collected and
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used to determine protein expression of siRNA target genes, intracellular
reactive oxygen species (ROS), and caspase-3 expression.

Coimmunoprecipitation and Western Immunoblotting
For coimmunoprecipitations with nuclear and cytosolic protein extracts from
Hepa-1 cells, ⬃300 g of extract was incubated with 2 g of anti-AHR
(BIOMOL Research Laboratories, Plymouth Meeting, PA) or anti-E2F1 (Santa
Cruz Biotechnology, Santa Cruz, CA) antibodies covalently coupled to protein A and G beads (Millipore, Billerica, MA) overnight at 4°C. Beads were
washed six times, suspended in 30 l of electrophoresis buffer, and boiled for
5 min. Eluted proteins were analyzed in 7.5% SDS-polyacrylamide gel electrophoresis (PAGE), and AHR and E2F1 were detected by Western immunoblot after semidry electrotransfer of the proteins to polyvinylidene difluoride
membranes. Antibodies against BAX and poly(ADP-ribose) polymerase
(PARP) were used for detection of these proteins in Off*Ahrb fibroblasts.
For coimmunoprecipitations from extracts of adenovirus-infected Saos-2
cells, cultures were infected with adenovirus vectors for 24 h and treated with
vehicle control or 5 nM TCDD for 2 h before harvesting for whole cell extracts.
Coimmunoprecipitation reactions were carried out as described above, using
⬃1 mg of whole cell extract incubated with 2 g of anti-AHR antibody. Eluted
proteins were analyzed in 7.5% SDS-PAGE, and RB, AHR, and E2F1 were
detected by Western immunoblotting.

Chromatin Immunoprecipitation (ChIP) Analyses
ChIP was performed with minor modifications of procedures described previously (Schnekenburger et al., 2007b). Chromatin from formaldehyde crosslinked Hepa-1 cells treated for 90 min with 5 nM TCDD or DMSO vehicle
were sheared to a size range of 0.3– 0.6 kb by sonication in a crushed-ice/
water bath with six 30-s bursts of 200 W, with a 30-s interval between bursts
using a Bioruptor (Diagenode, Sparta, NJ). Precleared chromatin was incubated overnight on a rotating platform at 4°C with rabbit polyclonal antibodies specific for AHR (SA-210; BIOMOL Research Laboratories), E2F1 (sc-193X;
Santa Cruz Biotechnology), or nonspecific rabbit immunoglobulin G (IgG)
(used as an immunoprecipitation control). The immunocomplexes were recovered by a 2-h incubation at 4°C with a 50% gel slurry of protein A-agarose
beads (Millipore). After extensive washing, precipitated chromatin complexes
were removed from the beads by incubation with elution buffer (50 mM
NaHCO3 and 1% SDS), with mild vortexing. This step was repeated, and the
eluates were combined. Cross-linking was reversed, and the samples were
sequentially digested with RNase A and proteinase K. DNA was purified by
chromatography on QIAquick columns (QIAGEN, Valencia, CA), eluted in
double distilled H2O, and an aliquot was used for analysis by real-time PCR
by using specific primers covering the region between ⫺4.8 kbp and ⫹0.1 kbp
of the mouse Apaf1 gene (Supplemental Table S3). PCR products were separated by electrophoresis through 15% polyacrylamide gels and visualized
after staining with ethidium bromide.

Total RNA Isolation, Reverse Transcription, and
Real-Time RT-PCR
Total cellular RNA was isolated with the RNeasy Mini kit (QIAGEN). Firststrand cDNAs were synthesized from 2 to 20 g of total RNA using SuperScript II reverse transcriptase (Invitrogen) and random primers. cDNAs were
subjected to PCR amplification with gene-specific primer sets (Supplemental
Table S4) for the various genes tested. Real-time quantitative PCR was performed using an Opticon 96-well rapid thermal cycler (MJ Research, Watertown, MA). A typical protocol included a 10-min denaturation step at 95°C
followed by 40 cycles of 95°C denaturation for 30 s, annealing for 30 s at a
primer-optimized temperature, and 72°C extension for 30 s. Detection of the
fluorescent product was carried out during the 72°C extension period, and
emission data were quantified using threshold cycle (Ct) values. Ct values for
all genes analyzed were determined two to six times, averaged, and means
were determined from the average Ct values for each biological duplicate. All
means were then normalized to values for ␤-actin. The relative or -fold change
from control Ct values was determined for each sample using the equation:
-fold change ⫽ 2⫺⌬⌬Ct, where ⌬⌬Ct ⫽ (CtTarget ⫺ CtActin)Test ⫺ (CtTarget ⫺
CtActin)Control. PCR product specificity from each primer pair was confirmed
using melting curve analysis and subsequent gel electrophoresis.

Analysis of Reactive Oxygen Species, DNA Damage, and
Apoptosis by Flow Cytometry
Relative levels of intracellular ROS were determined as described previously
(Peng et al., 2007). Briefly, cells cultured on 10-cm plates were trypsinized,
collected by centrifugation, and incubated in fetal bovine serum-free culture
medium with 5 M chloromethyl 2,7-dichlorofluorescein-diacetate (CMH2DCFDA) for 30 min at 37°C. Cells were washed and suspended at 1 ⫻ 106
cells/ml in PBS and analyzed in a FACSCalibur flow cytometer (BD Biosciences Immunocytometry Systems, San Jose, CA) equipped with a 488 argon
laser, for measurements of intracellular fluorescence. Mean log fluorescence
intensities were determined by the CELLQUEST software program (BD Biosciences). DNA damage was evaluated using a cell-based assay system (Millipore) for the detection of histone ␥H2A.X phosphorylated at Ser139 in fixed
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cells. After fixation, cells were incubated with fluorescein isothiocyanate
(FITC)-conjugated anti-phospho-histone H2A.X (Ser139) or negative control
mouse IgG-FITC and analyzed by flow cytometry. Fluorescent signals were
gated at an intensity such that ⬍2% of the negative control cells would score
as positive. For analysis of apoptotic cells, we used a flow cytometry kit to
detect activated caspase-3 (BD Biosciences). Cells were harvested by
trypsinization, fixed, incubated with a phycoerythrin (PE)-conjugated monoclonal rabbit anti-active caspase-3 antibody and analyzed by flow cytometry.
In some cases, apoptosis was assessed from the fraction of sub-G0/G1 cells
observed in cell cycle analyses of propidium iodide-stained cells.

RESULTS
Loss of AHR Increases Intracellular ROS Levels, Leading
to DNA Damage and E2F1-dependent Apoptosis
AHR ablation in mice is associated with increased apoptosis
in the liver by mechanisms as yet uncharacterized (Elizondo
et al., 2000). Because of the known role of the AHR in cell
cycle regulation, we suspected that loss of AHR might lead
to loss of a cell cycle checkpoint, which in turn would drive
the cells toward an apoptotic pathway. To explore this possibility, we made use of the cell line Off*Ahrb, a TET-OFF
stable transfectant derived from MEFs from AHR knockout
mice (Chang et al., 2007). These cells carry a TET-OFF–
regulated vector expressing the high-affinity AHR receptor
encoded by the Ahrb1 allele. Repression or expression of the
AHR protein in these fibroblasts depends solely on the
presence or absence, respectively, of Dox in the culture
medium, hence ruling out genetic differences between
clonally unrelated cell lines as a potential source of confounding results. Growth of these cells in the absence of Dox
causes them to express the AHR protein, to proliferate at a
significantly faster rate, and to deregulate expression of
many cell cycle and extracellular matrix genes, compared
with cells grown in the presence of Dox and hence lacking
AHR expression. Furthermore, exposure to a prototypical
AHR ligand or deletion of the ligand-binding domain has
not effect on these AHR functions, indicating that they are
truly independent of ligand (Chang et al., 2007).
In Off*Ahrb cells, treatment with Dox for 48 –72-h represses AHR expression to undetectable levels (Figure 1A).
Concomitantly with the AHR repression, BAX expression
and PARP cleavage, two well-characterized markers of apoptosis, are both induced (Figure 1A). Dox treatment fails to
elicit similar effects from AHR-positive fibroblast cells (Figure 1A), ruling out the trivial explanation that these effects
might be caused by Dox itself and thus be unrelated to AHR
expression. Consistent with these data, we observe an approximate doubling of the number of cell expressing activated caspase-3 in cells treated with Dox (AHR negative)
relative to untreated cells (AHR positive) (Figure 1B),
thereby confirming that, as in mouse liver (Elizondo et al.,
2000), the lack of AHR expression is also proapoptotic in
cultured cells.
To determine whether the increase in apoptosis is the result
of a higher level of ROS in AHR-negative cells, we labeled
Dox-treated and -untreated cells with CM-H2DCFDA and
identified ROS-activated fluorescence-positive cells by flow
cytometry. The fluorescence intensity of Dox-treated cells
was significantly higher than the intensity of Dox-untreated
cells or of cells that were not exposed to CM-H2DCFDA,
with about threefold more CM–H2DCFDA positive cells in
the Dox-treated, AHR-negative group (Figure 1C), indicating that the absence of AHR results in a higher intrinsic
oxidant level.
Persistently high ROS levels are highly reactive and interact with all cellular macromolecules, including DNA, inducing strand breaks and other forms of DNA damage. Phos3265
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Figure 1. Loss of the Ahr gene causes oxidative stress resulting in DNA damage and apoptosis. (A) Off*Ahrb and Ahr⫹/⫹ fibroblasts were
treated with 5 g/ml Dox for 0, 24, 48, and 72 h and analyzed by Western immunoblotting for the expression of AHR, BAX, and PARP
proteins. The arrow points at the 89-kDa C-terminal PARP cleavage product resulting from caspase-3/7 activity. Actin was used as a loading
control. (B) Detection of activated caspase-3 by flow cytometry. Off*Ahrb cells were treated with 5 g/ml Dox (red trace) for 48 h or mock
treated with an equivalent volume (never to exceed 0.1% of the total volume of culture) of 70% ethanol vehicle (green trace), fixed, and
allowed to react with PE-labeled active caspase-3 antibodies. Control cells (purple trace) were unexposed to antibodies. The inset shows the
percentage of caspase-3–positive cells, as determined by the CELLQUEST software. (C) Detection of intracellular oxidative stress by flow
cytometry. Off*Ahrb cells treated as described in B were exposed to CM-H2DCFDA for 30 min at 37°C and subsequently analyzed by flow
cytometry. The purple tracing corresponds to cells unexposed to DCFDA; red and green tracings are for cell treated with Dox or untreated,
respectively. The inset represents the percentage of DCFDA-positive cells as determined by the CELLQUEST software. (D) Detection of
␥H2A.X. Off*Ahrb cells were treated with Dox (red tracing) or left untreated (green tracing) as described above, fixed, and allowed to interact
with FITC-tagged antibodies to H2A.X phosphorylated at Ser139 (red and green tracings) or with a control FITC-tagged mouse IgG (purple
tracing). The inset represents the percentage of ␥H2A.X-positive cells as determined by the CELLQUEST software. The values shown in all
graphs correspond to the mean ⫾ SD of four to six experiments. *p ⬍ 0.05 and **p ⬍ 0.01.

phorylation of histone H2A.X is a marker of DNA damage,
often used as a surrogate for direct DNA damage assays
(Tanaka et al., 2007). We therefore used an antibody to
phosphorylated ␥H2A.X to measure the extent of DNA
damage in Dox-treated and -untreated cells by flow cytometry. Dox-treated, AHR-negative cells showed higher fluorescence intensities than AHR-positive cells, corresponding
to ⬃3 times the number of ␥H2A.X-positive cells and indicative of a greater extent of DNA damage in cells lacking
AHR (Figure 1D).
DNA damage is known to activate the ATM-CHK2-E2F1
apoptosis pathway (Stevens and La Thangue, 2004). To determine whether increases in ROS and DNA damage resulting from loss of AHR would also induce E2F1-mediated
apoptosis, we assessed activated caspase-3 levels after
knockdown of E2F1 expression. Forty-eight hours after
transfection into Dox-treated Off*Ahrb fibroblasts, two different siRNAs blocked E2F1 expression by 70 –90% in comparison with cells transfected with a scrambled RNA control
or either untransfected or untreated cells (Figure 2A). Blocking E2F1 expression did not change the level of intracellular
ROS in AHR-negative cells, as determined from the fluorescence intensity of Dox-treated cells exposed to CM-H2DCFDA
3266

(Figure 2B). Conversely, E2F1 siRNA significantly reduced
the number of activated caspase-3 positive, Dox-treated cells
compared with a scrambled RNA control, whereas it had no
effect in Dox-untreated, AHR-positive cells (Figure 2, C and
D). These results suggest that loss of AHR triggers a sequence of events that includes an elevated intracellular oxidant state and DNA damage, ultimately leading to E2F1mediated induction of apoptosis.
AHR Activation Protects Cells from Etoposide-induced
Apoptosis
TCDD treatment inhibits p53-dependent induction of apoptosis by UV in primary rat hepatocytes in culture (Worner
and Schrenk, 1996; Schrenk et al., 2004), suggesting that AHR
activation might also block apoptosis induced by the DNA
damage-CHK2-E2F1 pathway. To test this hypothesis, we
followed the fate of TCDD-treated Off*Ahrb cells exposed to
the DNA-damaging agent etoposide. Cells were grown in
the presence or absence of Dox for 48 h, followed by treatment for an additional 48 h with 5 nM TCDD or DMSO
vehicle and with increasing etoposide concentrations. The
etoposide dose-response curve of AHR-expressing cells
treated with TCDD showed a significant increase in cell
Molecular Biology of the Cell
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Figure 2. Inhibition of E2F1 with siRNA blocks apoptosis induced by loss of AHR. (A) siRNA inhibits E2F1 expression. Off*Ahrb cells grown
for 48 h in the presence of 5 g/ml Dox were transfected with two different siRNA oligonucleotides or with a negative, scrambled RNA
control (for details, see Materials and Methods), and 48 h later proteins were extracted for detection of E2F1 by immunoblotting. Controls
included cells not treated with Dox and cells treated with Dox but not transfected with siRNA. To ensure the loss of AHR expression in the
appropriate treatments, the blots was also probed with anti-AHR antibodies. Actin was used as a loading control. We estimate that siRNA
inhibited expression of E2F1 by 70 –90%. (B) E2F1 inhibition did not block oxidative stress due to loss of AHR expression. Off*Ahrb cells were
treated with 5 g/ml Dox for 48 h and transfected with E2F1 siRNA (red trace) or scrambled control RNA (green trace). After 48 h in culture,
transfected cells were exposed to CM-H2DCFDA for 30 min at 37°C and subsequently analyzed by flow cytometry. The purple tracing
corresponds to cells unexposed to DCFDA. Note that inhibition of E2F1 expression did not change the oxidative stress levels in the cells. (C)
Detection of activated caspase-3 by flow cytometry in Off*Ahrb cells treated with 5 g/ml Dox for 48 h and transfected with E2F1 siRNA
(green trace) or scrambled control RNA (red trace), fixed and allowed to react with PE-labeled active caspase-3 antibodies. The inset shows
results from a similar experiment using control Off*Ahrb cells grown for 48 h in the absence of Dox and transfected with the same siRNA
(green) or scrambled control (red). (D) CELLQUEST integration of the data in C, showing the percentage of caspase-3–positive cells as a
function of Dox and siRNA transfection regime. The values shown are the mean ⫾ SD of four determinations. **p ⬍ 0.01.

survival relative to the same etoposide concentrations in
cells treated with DMSO vehicle, an effect that did not take
place in similarly treated cells in which AHR expression was
repressed by Dox treatment (Figure 3, A and B). These
results suggest that AHR activation may also protect cells
from death by the E2F1-dependent apoptosis pathway.
AHR Forms Complexes with E2F
AHR forms complexes with RB and enhances RB-mediated
repression of E2F target genes (Puga et al., 2000). We asked
whether AHR could also form complexes with E2F that were
independent of the presence of RB. Transient expression of
the luciferase reporter plasmid p3XE2FLuc in mouse Hepa-1
and in human Saos-2 cells, both lacking RB expression, was
repressed by expression of activated AHR to the same extent
as by expression of RB (Supplemental Figure S2, A and B).
As reported previously (Puga et al., 2000), coexpression of
Vol. 19, August 2008

AHR and RB resulted in additive repression of E2F reporter
gene expression. These results suggested that AHR could
not only interact with RB but also with E2F. Subsequent
experiments using expression vectors bearing AHR truncation mutants (Puga et al., 2000) showed that deletion of the
region between amino acid residues 322 and 495, including
the ligand binding domain and part of the PAS B domain,
led to loss of the ability of AHR to repress the E2F target
(Supplemental Figure S2, C and D), identifying this domain
as the most likely area of AHR–E2F functional interactions.
Coimmunoprecipitation experiments with crude extracts
from Saos-2 cells infected with the adenoviral expression
vectors Ad-AHR, Ad-E2F1, and Ad-RB showed that the
AHR forms immune complexes with the other two proteins,
either when only two or all three of them were overexpressed (Figure 3C), suggesting that AHR has no specific
binding preference for either RB or E2F1 and that it can bind
3267
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Figure 3. The activated AHR protects from etoposideinduced cell death and coimmunoprecipitates with
E2F1. Off*Ahrb cells grown for 48 h without Dox (A) or
with 5 g/ml Dox (B) were treated with the indicated
concentration of etoposide in the presence of 5 nM
TCDD or DMSO vehicle. After an additional 48 h, cell
numbers were determined by Hoescht 33258 staining,
by using a standard curve relating Hoescht fluorescence
to cell numbers (Chang et al., 2007). **p ⬍ 0.01. (C)
Saos-2 cells were infected at 100 pfu/cell with purified
adenoviral expression vectors for LacZ, AHR, RB, and
E2F1 in the combinations indicated. After 24 h, cells
were treated with 5 nM TCDD for 2 h and harvested for
whole cell extracts. Coimmunoprecipitations were carried out on 1 mg of total protein extract with 2 g of
anti-AHR antibody, and eluted proteins were analyzed
by Western blot. (D) AHR coimmunoprecipitates with
E2F1 from Hepa-1 cell extracts. Cells were treated with
5 nM TCDD or vehicle control for 1 h. Nuclear extracts
(300 –500 g of total protein) were precleared by incubation with 10 l of a protein A/G bead mixture for 1 h
at 4°C. Supernatants were transferred to tubes containing 1 g of either an AHR or an E2F1 polyclonal antibody covalently bound to protein
A/G beads, followed by overnight incubation at 4°C. After thorough washing, beads were boiled in SDS gel loading buffer, and supernatants
were analyzed by SDS-PAGE and Western blot using the corresponding antibodies. An aliquot of each crude extracts was equally analyzed
for comparison.

equally well with either in the presence of the other. To
determine whether RB was required for the formation of
AHR–E2F1 complexes, we used nuclear extracts from RBnegative Hepa-1 cells in coimmunoprecipitation experiments. Immunoblotting with anti-E2F1 showed that antiAHR antibodies precipitated E2F1 from nuclear extracts of
TCDD treated cells but not from cells treated with DMSO
control. Conversely, immunoblotting with anti-AHR showed
that anti-E2F1 antibodies immunoprecipitated AHR from
nuclear extracts of TCDD-treated cells but not from DMSOtreated cells (Figure 3D). These data strongly indicate that
AHR and E2F1 associate in a manner independent of RB and
that ligand is needed to mediate AHR nuclear translocation
and interaction with E2F1, which resides solely in the nucleus. We tested two other E2F family members, E2F3 and
E2F4, by using the adenoviral expression system, both of
which were as competent in forming complexes with AHR
as E2F1 (data not shown).
AHR Represses E2F1-dependent Transactivation of Apaf1
and p73 and Inhibits Apoptosis
The observation that the activated AHR represses E2F1induced apoptosis and forms complexes with members of
the E2F family, particularly E2F1, prompted us to test
whether this effect results directly from AHR–E2F1 complex
formation. We first tested the effect of AHR activation on
Apaf1 and p73 induction in Hepa-1 cells transfected with a
constitutively active CHK2 expression vector. Active CHK2CA, but not kinase-dead CHK2-KD, induced Apaf1 by about
sixfold, and TCDD treatment inhibited the induction (Figure
4A). Expression of p73, as measured with a set of exon 14
primers that would detect the ␣ variants of both TAp73 and
DNp73 isoforms, was induced 18-fold, but primers bracketing exons 2 and 3, specific for the proapoptotic TAp73 isoform, showed a 35-fold level of induction, almost twice as
high as detected with the exon 14 primers, strongly indicating that there was little or no induction of the antiapoptotic
DNp73 isoform and that C-terminal variants other than ␣
might also be induced. As was the case for Apaf1, induction
of TAp73 was significantly reduced by treatment with
TCDD (Figure 4A), suggesting that the interaction of acti3268

vated AHR with E2F1 suppresses the transactivation of proapoptotic E2F1 target genes.
A direct test of this hypothesis made use of the Saos-2
human osteosarcoma cells, in which E2F1 overexpression
and stabilization have been shown to induce apoptosis (Moroni et al., 2001; Stevens et al., 2003). Infection of these cells
with the Ad-E2F1 expression vector induced accumulation
of Apaf1 and TAp73 mRNA by 4.5- and 14-fold, respectively
(Figure 4B). As expected, RB overexpression completely repressed the induction of both genes, as was the case when
AHR was overexpressed by the corresponding adenoviral
vector (Figure 4B). Neither RB, AHR, nor an adenoviral
expression vector for ␤-galactosidase induced or repressed
significantly the target genes when expressed alone.
Repression of proapoptotic E2F1 targets by AHR resulted
in inhibition of apoptosis, as determined by flow cytometry
analyses of sub-G0/G1 Saos-2 cells transfected with expression plasmids for E2F1, AHR, and RB. In these experiments,
plasmid pH2BGFP, expressing green fluorescent protein
(GFP) fused to histone H2B, was included to tag the nuclei of
transfected cells, and to thereby distinguish between transfected and untransfected cells. E2F1 expression increased the
fraction of sub-G0/G1 cells by five- to sixfold relative to
control cells transfected only with the GFP expression vector. Neither RB nor AHR caused a significant increase over
the control. However, RB, and more so AHR, significantly
decreased the sub-G0/G1 fraction induced by E2F1. These
effects were evident only in the transfected, GFP-positive
cells, and not in the total cell population, indicating that the
observations were due to the expression of the transfected
genes.
AHR and E2F1 Form Complexes at E2F1 Binding Motifs
on the Apaf1 Promoter
The formation of complexes between AHR and E2F1 could
be unrelated to the observed effect of AHR expression on
E2F1-induced transactivation and apoptosis. For example,
there could be no connection between molecular interactions
and biological effects, the one taking place in the nuclear
matrix milieu and the other resulting from AHR binding to
its consensus sites in the promoter of E2F1 target genes.
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Figure 4. AHR-E2F1 interactions repress Apaf1 and p73 expression and inhibit apoptosis. (A) Ligand activation of the AHR represses
CHK2-dependent induction of Apaf1 and p73. Mouse hepatoma Hepa-1 cells were transfected with a constitutively active CHK2 expression
plasmid (CHK2-CA) or its kinase-dead counterpart (CHK2-KD). After selection for 10 d in G418, cells were treated with 5 nM TCDD or with
DMSO vehicle, and 12 h later they were harvested and total RNA was extracted for determination of mRNA levels of Apaf1, p73, using both
primers that detect transcripts common to TAp73 and DNp73 (middle) and primers specific for TAp73 (bottom), and ␤-actin control by
real-time RT-PCR. The values shown are the mean ⫾ SD of three determinations relative to ␤-actin. (B) AHR and RB overexpression inhibit
Apaf1 and p73 induction by overexpression of E2F1. Saos-2 cells were infected with 100 pfu/cell of the adenoviral expression vectors AdE2F1,
AdLacZ, AdRB, and AdAHR in the combinations indicated in the figure. RNA was extracted 24 h after infection and used to determine
mRNA levels of Apaf1, p73 and ␤-actin control by real-time RT-PCR. The values shown are the mean ⫾ SD of three determinations relative
to ␤-actin. As shown previously (Puga et al., 2000; Marlowe et al., 2004) no ligand is necessary to activate the AHR in these cells. (C) AHR
and RB inhibit apoptosis induction by E2F1. Saos-2 cells were transfected with plasmid vectors for expression of E2F1, GFP fused to histone
H2B, RB, and AHR in the combinations indicated in the figure. Twenty-four hours after transfection, cells were analyzed by flow cytometry
after propidium iodide staining. Total and GFP-positive sub-G0/G1 cells were scored separately to discriminate between the total and the
transfected cell populations.

Alternatively, the AHR could be recruited to canonical E2F1
binding motifs by E2F1 itself and function as an active
repressor of E2F1 transactivation. To distinguish between
these alternatives, we used chromatin immunoprecipitation
to analyze AHR and E2F1 binding in the promoter regions of
E2F1 target genes.
Anti-E2F and anti-AHR antibodies were used to immunoprecipitate Apaf1 promoter chromatin from Hepa-1 cells
treated with 5 nM TCDD or DMSO control for 90 min. Mock
immunoprecipitations were conducted as a control with
nonimmune rabbit IgG. The assays were associated with a
systematic mapping of the promoter, by using primer pairs
for PCR amplification distributed approximately every 300
base pairs, between positions ⫺4.8 kb and ⫹0.1 kb from the
transcription start site (Supplemental Table S3). In control
and TCDD-treated cells, anti-E2F antibodies precipitated
several Apaf1 promoter regions to a significantly greater
extent than the control IgG. Several of these promoter regions contained consensus E2F binding sites, in particular
those in the transcriptional start site-proximal domain,
whereas others did not, consistent with previous observations (Wells et al., 2002). In contrast, anti-AHR antibodies
precipitated a single promoter domain from TCDD-treated
but not from DMSO-treated cells. This domain was localized
to the ⫺1400 region from the transcriptional start site, far
from any of the canonical AHR binding sites in the Apaf1
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gene but flanked by two E2F consensus sites and coinciding
with an area where E2F antibodies also bound (Figure 5).
These data suggest that the molecular interaction between
the AHR and E2F1 proteins takes place at the promoters of
proapoptotic E2F1 target genes.
DISCUSSION
The results presented in this article show that deletion of the
Ahr gene creates a condition of heightened cellular oxidative
stress, followed by a significant level of DNA damage, quantifiable by the increase of Ser139-phosphorylated ␥H2A.X
histone. The higher pro-oxidant status and DNA damage in
AHR-negative cells promotes E2F1-mediated apoptosis,
which can be inhibited by E2F1 knockdown with siRNA.
These data uncover an oxidative stress pathway that connects the loss of AHR with the activation of E2F1 apoptotic
functions. These functions are also induced by the DNAdamaging agent etoposide, and we find that etoposide-induced cell death in AHR-positive cells is blocked by AHR
activation, which, through its interaction with E2F1, attenuates the latter’s proapoptotic function. The interaction between AHR and E2F is independent of the retinoblastoma
protein, because AHR coimmunoprecipitates with E2F in
extracts from RB-negative cells, and, because, by blocking
apoptosis, AHR–E2F1 interactions have a diametrically op3269

J. L. Marlowe et al.
Figure 5. AHR and E2F1 interact on the
promoter of the Apaf1 gene. The region of
the Apaf1 promoter comprised between ⫺4.8
kbp and ⫹0.1 kbp was scanned by chromatin immunoprecipitation analyses using antibodies to AHR, E2F1, or nonimmune IgG.
Hepa-1 cells were treated with 5 nM TCDD
or with DMSO vehicle, and 90 min later they
were fixed with formaldehyde and processed for ChIP analyses. The values shown
represent the log2 ratios of the real-time PCR
amplification data of chromatin immunoprecipitated with anti-AHR, anti-E2F1, or nonimmune IgG. The values shown represent
the average of two determinations ⫾ SD.
Position of canonical binding sites for AHR
and E2F are denoted by the red and green bars, respectively drawn along the length of the promoter.

posite end point, promoting, rather than inhibiting, proliferation.
Cell cycle progression, differentiation, apoptosis, and senescence are major regulatory targets of the E2F proteins,
and they are also major AHR targets (Puga et al., 2005;
Marlowe and Puga, 2005; Bock and Kohle, 2006). Multiple
redundant pathways couple proliferation with apoptosis
and protect cells when normal proliferation controls are lost
(Tsantoulis and Gorgoulis, 2005). One striking example of
this coupling involves the activities of the E2F1 protein,
which in addition to controlling gene expression for cell
cycle progression, also activates apoptosis when DNA-damaging agents activate the ATM–CHK2 signaling pathway,
phosphorylating E2F1 at serine-364 (Phillips et al., 1997;
Phillips and Vousden, 2001; Stevens and La Thangue, 2004).
Because H2A.X phosphorylation at Ser139 is also due to
activation of the ATM–CHK2 pathway (Agarwal et al., 2006),
we surmise that E2F1 is also phosphorylated by CHK2 and
stabilized in our cells, although the lack of antibodies that
recognize mouse p-Ser-368-E2F1 (equivalent to human
p-Ser-364-E2F1) precludes us from directly testing this conclusion.
Activation by ligand translocates the AHR into the nucleus, where it physically interacts with E2F1 and causes the
inhibition of E2F1-mediated apoptosis. Expression analyses
and ChIP assays suggest that the mechanistic order of events
leading to this outcome starts by the repression of CHK2mediated induction of the proapoptotic E2F1 target genes,
Apaf1 and TAp73 (and possibly others). Repression results
from the interaction between AHR and E2F1, which, at least
in the case of Apaf1, takes place at a canonical E2F1 binding
motif in its promoter. The nature of the specific chromatin
remodeling complexes generated by this interaction and
how they function in gene repression are unexplored at this
time. Figure 6 schematically represents these mechanistic
events. DNA damage in general, or specifically due to loss of
AHR, causes induction of the E2F1 apoptotic pathway
(Stevens and La Thangue, 2004), proceeding through CHK2
activation, E2F1 phosphorylation, induction of proapoptotic
genes and ultimately, cell death. At this point, we surmise
that CHK2 activity and E2F1 phosphorylation also result
from AHR loss. Conversely, AHR activation causes it to
complex with E2F1 and block proapoptotic gene induction,
presumably by blocking E2F1 phosphorylation by CHK2,
and ultimately leading to an antiapoptotic endpoint.
Induction of apoptosis is consistent with the role of E2F1
as a tumor suppressor, a role confirmed by the finding that
E2F1-deficient mice develop a range of tumor types (Field et
al., 1996; Yamasaki et al., 1996). Inhibition of apoptosis, in
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Figure 6. Schematic representation of the outcome of AHR–E2F1
interactions. DNA damage, in general, or specifically due to loss of
AHR, causes induction of the E2F1 apoptotic pathway, which proceeds through CHK2 activation, E2F1 phosphorylation, induction of
proapoptotic genes, and apoptosis. The question marks indicate that
at present we do not know whether CHK2 activity and E2F1 phosphorylation also result from AHR loss. AHR activation causes it to
complex with E2F1 and block proapoptotic gene induction by blocking CHK2 phosphorylation of E2F1, ultimately leading to an antiapoptotic endpoint.

contrast, is consistent with a mechanism of tumor promotion/progression. In diethylnitrosamine (DEN)-initiated
rats, both acute and chronic treatment with TCDD results in
an approximate 10-fold decrease in the rate of apoptosis in
preneoplastically transformed liver foci, with no effect on
the background rate of apoptosis in normal hepatocytes
(Stinchcombe et al., 1995). Furthermore, AHR activation by
TCDD blocks UV irradiation-induced apoptosis (Worner
and Schrenk, 1996; Schrenk et al., 2004). The capacity of
various Ah receptor ligands to act as tumor promoters has
been attributed to their ability to inhibit the apoptotic elimination of initiated cells bearing genotoxic lesions (Schwarz
et al., 2000). Our data suggest that they may do so by
activating the AHR and inhibiting apoptosis through repression of E2F1 proapoptotic target genes, thus preventing the
elimination of cells that have lost normal cell cycle control
and promoting their proliferation. In this context, the activated AHR would effectively function as an oncogene.
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